CoChat

A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia

Open access
van der Ende, Emma L, Bron, Esther E, Poos, Jackie M, Jiskoot, Lize C, Panman, Jessica L, Papma, Janne M, Meeter, Lieke H, Dopper, Elise G P, Wilke, Carlo, Synofzik, Matthis, Heller, Carolin, Swift, Imogen J, Sogorb-Esteve, Aitana, Bouzigues, Arabella, Borroni, Barbara, Sanchez-Valle, Raquel, Moreno, Fermin, Graff, Caroline, Laforce, Robert, Galimberti, Daniela, Masellis, Mario, Tartaglia, Maria Carmela, Finger, Elizabeth, Vandenberghe, Rik, Rowe, James B, de Mendonça, Alexandre, Tagliavini, Fabrizio, Santana, Isabel, Ducharme, Simon, Butler, Christopher R, Gerhard, Alexander, Levin, Johannes, Danek, Adrian, Otto, Markus, Pijnenburg, Yolande A L, Sorbi, Sandro, Zetterberg, Henrik, Niessen, Wiro J, Rohrer, Jonathan D, Klein, Stefan, van Swieten, John C, Venkatraghavan, Vikram, Seelaar, Harro, GENFI consortium, Afonso, Sónia, Almeida, Maria Rosario, Anderl-Straub, Sarah, Andersson, Christin, Antonell, Anna, Archetti, Silvana, Arighi, Andrea, Balasa, Mircea, Barandiaran, Myriam, Bargalló, Nuria, Bartha, Robart, Bender, Benjamin, Benussi, Alberto, Benussi, Luisa, Bessi, Valentina, Binetti, Giuliano, Black, Sandra, Bocchetta, Martina, Borrego-Ecija, Sergi, Bras, Jose, Bruffaerts, Rose, Cañada, Marta, Cantoni, Valentina, Caroppo, Paola, Cash, David, Castelo-Branco, Miguel, Convery, Rhian, Cope, Thomas, Di Fede, Giuseppe, Díez, Alina, Duro, Diana, Fenoglio, Chiara, Ferrari, Camilla, Ferreira, Catarina B, Fox, Nick, Freedman, Morris, Fumagalli, Giorgio, Gabilondo, Alazne, Gasparotti, Roberto, Gauthier, Serge, Gazzina, Stefano, Giaccone, Giorgio, Gorostidi, Ana, Greaves, Caroline, Guerreiro, Rita, Hoegen, Tobias, Indakoetxea, Begoña, Jelic, Vesna, Karnath, Hans-Otto, Keren, Ron, Langheinrich, Tobias, Leitão, Maria João, Lladó, Albert, Lombardi, Gemma, Loosli, Sandra, Maruta, Carolina, Mead, Simon, Miltenberger, Gabriel, van Minkelen, Rick, Mitchell, Sara, Moore, Katrina, Nacmias, Benedetta, Nicholas, Jennifer, Öijerstedt, Linn, Olives, Jaume, Ourselin, Sebastien, Padovani, Alessandro, Peakman, Georgia, Pievani, Michela, Pijnenburg, Yolande, Polito, Cristina, Premi, Enrico, Prioni, Sara, Prix, Catharina, Rademakers, Rosa, Redaelli, Veronica, Rittman, Tim, Rogaeva, Ekaterina, Rosa-Neto, Pedro, Rossi, Giacomina, Rosser, Martin, Santiago, Beatriz, Scarpini, Elio, Schönecker, Sonja, Semler, Elisa, Shafei, Rachelle, Shoesmith, Christen, Tábuas-Pereira, Miguel, Tainta, Mikel, Taipa, Ricardo, Tang-Wai, David, Thomas, David L, Thompson, Paul, Thonberg, Hakan, Timberlake, Carolyn, Tiraboschi, Pietro, Todd, Emily, Van Damme, Philip, Vandenbulcke, Mathieu, Veldsman, Michele, Verdelho, Ana, Villanua, Jorge, Warren, Jason, Woollacott, Ione, Wlasich, Elisabeth, Zulaica, Miren · 2022 · Brain
Cited by 58

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Several CSF and blood biomarkers for genetic frontotemporal dementia have been proposed, including those reflecting neuroaxonal loss (neurofilament light chain and phosphorylated neurofilament heavy chain), synapse dysfunction [neuronal pentraxin 2 (NPTX2)], astrogliosis (glial fibrillary acidic protein) and complement activation (C1q, C3b). Determining the sequence in which biomarkers become abnormal over the course of disease could facilitate disease staging and help identify mutation carriers with prodromal or early-stage frontotemporal dementia, which is especially important as pharmaceutical trials emerge. We aimed to model the sequence of biomarker abnormalities in presymptomatic and symptomatic genetic frontotemporal dementia using cross-sectional data from the Genetic Frontotemporal dementia Initiative (GENFI), a longitudinal cohort study. Two-hundred and seventy-five presymptomatic and 127 symptomatic carriers of mutations in GRN, C9orf72 or MAPT, as well as 247 non-carriers, were selected from the GENFI cohort based on availability of one or more of the aforementioned biomarkers. Nine presymptomatic carriers developed symptoms within 18 months of sample collection (‘converters’). Sequences of biomarker abnormalities were modelled for the entire group using discriminative event-based modelling (DEBM) and for each genetic subgroup using co-initialized DEBM. These models estimate probabilistic biomarker abnormalities in a data-driven way and do not rely on previous diagnostic information or biomarker cut-off points. Using cross-validation, subjects were subsequently assigned a disease stage based on their position along the disease progression timeline. CSF NPTX2 was the first biomarker to become abnormal, followed by blood and CSF neurofilament light chain, blood phosphorylated neurofilament heavy chain, blood glial fibrillary acidic protein and finally CSF C3b and C1q. Biomarker orderings did not differ significantly between genetic subgroups, but more uncertainty was noted in the C9orf72 and MAPT groups than for GRN. Estimated disease stages could distinguish symptomatic from presymptomatic carriers and non-carriers with areas under the curve of 0.84 (95% confidence interval 0.80–0.89) and 0.90 (0.86–0.94) respectively. The areas under the curve to distinguish converters from non-converting presymptomatic carriers was 0.85 (0.75–0.95). Our data-driven model of genetic frontotemporal dementia revealed that NPTX2 and neurofilament light chain are the earliest to change among the selected biomarkers. Further research should investigate their utility as candidate selection tools for pharmaceutical trials. The model’s ability to accurately estimate individual disease stages could improve patient stratification and track the efficacy of therapeutic interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awab382

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 36

  1. Lashley, 2015, Review: An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations, Neuropathol Appl Neurobiol, 41, 858, 10.1111/nan.12250 · DOI · Paper page
  2. Desmarais, 2019, Therapeutic trial design for frontotemporal dementia and related disorders, J Neurol Neurosurg Psychiatry, 90, 412, 10.1136/jnnp-2018-318603 · DOI · Paper page
  3. Wilke, 2019, Correlations between serum and CSF pNfH levels in ALS, FTD and controls: A comparison of three analytical approaches, Clin Chem Lab Med, 57, 1556, 10.1515/cclm-2019-0015 · DOI · Paper page
  4. Rohrer, 2016, Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia, Neurology, 87, 1329, 10.1212/WNL.0000000000003154 · DOI · Paper page
  5. Eng, 1994, GFAP and astrogliosis, Brain Pathol, 4, 229, 10.1111/j.1750-3639.1994.tb00838.x · DOI · Paper page
  6. Rutkowski, 2010, Complement and the central nervous system: Emerging roles in development, protection and regeneration, Immunol Cell Biol, 88, 781, 10.1038/icb.2010.48 · DOI
  7. Venkatraghavan, 2019, Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling, Neuroimage, 186, 518, 10.1016/j.neuroimage.2018.11.024 · DOI · Paper page
  8. Panman, 2021, Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia, J Neurol Neurosurg Psychiatry, 92, 494, 10.1136/jnnp-2020-323541 · DOI · Paper page
  9. Oxtoby, 2018, Data-driven models of dominantly-inherited Alzheimer's disease progression, Brain, 141, 1529, 10.1093/brain/awy050 · doi:10.1093/brain/awy050
  10. Archetti, 2019, Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease, Neuroimage Clin, 24, 101954, 10.1016/j.nicl.2019.101954 · DOI · Paper page
  11. Venkatraghavan, 2021, Analyzing the effect of APOE on Alzheimer's disease progression using an event-based model for stratified populations, Neuroimage, 227, 117646, 10.1016/j.neuroimage.2020.117646 · DOI
  12. Oxtoby, 2021, Sequence of clinical and neurodegeneration events in Parkinson's disease progression, Brain, 144, 975, 10.1093/brain/awaa461 · DOI · Paper page
  13. Gabel, 2020, Evolution of white matter damage in amyotrophic lateral sclerosis, Ann Clin Transl Neurol, 7, 722, 10.1002/acn3.51035 · DOI
  14. Dekker, 2021, The sequence of structural, functional and cognitive changes in multiple sclerosis, Neuroimage Clin, 29, 102550, 10.1016/j.nicl.2020.102550 · DOI
  15. Preische, 2019, Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease, Nat Med, 25, 277, 10.1038/s41591-018-0304-3 · DOI · Paper page
  16. Benatar, 2019, Neurofilaments in pre-symptomatic ALS and the impact of genotype, Amyotroph Lateral Scler Frontotemporal Degener, 20, 538, 10.1080/21678421.2019.1646769 · DOI · Paper page
  17. Gorno-Tempini, 2011, Classification of primary progressive aphasia and its variants, Neurology, 76, 1006, 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
  18. Malone, 2015, Accurate automatic estimation of total intracranial volume: A nuisance variable with less nuisance, Neuroimage, 104, 366, 10.1016/j.neuroimage.2014.09.034 · DOI · Paper page
  19. Ling, 2018, Synaptic paths to neurodegeneration: The emerging role of TDP-43 and FUS in synaptic functions, Neural Plast, 2018, 8413496, 10.1155/2018/8413496 · DOI · Paper page
  20. Marttinen, 2015, Synaptic dysfunction and septin protein family members in neurodegenerative diseases, Mol Neurodegener, 10, 16, 10.1186/s13024-015-0013-z · DOI · Paper page
  21. Terry, 1991, Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment, Ann Neurol, 30, 572, 10.1002/ana.410300410 · DOI · Paper page
  22. Petzold, 2009, Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy, J Neurol Sci, 279, 76, 10.1016/j.jns.2008.12.037 · DOI
  23. Zucchi, 2018, A motor neuron strategy to save time and energy in neurodegeneration: Adaptive protein stoichiometry, J Neurochem, 146, 631, 10.1111/jnc.14542 · DOI
  24. Kušnierová, 2019, Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels, J Clin Lab Anal, 33, e22948, 10.1002/jcla.22948 · DOI
  25. Benatar, 2020, Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS, Neurology, 95, e59, 10.1212/WNL.0000000000009559 · DOI · Paper page
  26. Lu, 2015, Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: Insights from a longitudinal study, J Neurol Neurosurg Psychiatry, 86, 565, 10.1136/jnnp-2014-307672 · DOI · Paper page
  27. Adiutori, 2018, The proteome of neurofilament-containing protein aggregates in blood, Biochem Biophys Rep, 14, 168
  28. Lu, 2011, A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect, J Neurosci Methods, 195, 143, 10.1016/j.jneumeth.2010.11.026 · DOI
  29. Petzold, 2003, A specific ELISA for measuring neurofilament heavy chain phosphoforms, J Immunol Methods, 278, 179, 10.1016/S0022-1759(03)00189-3 · DOI · Paper page
  30. Jiskoot, 2016, Presymptomatic cognitive decline in familial frontotemporal dementia: A longitudinal study, Neurology, 87, 384, 10.1212/WNL.0000000000002895 · DOI · Paper page
  31. Jiskoot, 2018, Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia, J Neurol, 265, 1381, 10.1007/s00415-018-8850-7 · DOI · Paper page
  32. Valente, 2019, Phenocopy syndrome of behavioral variant frontotemporal dementia: A systematic review, Alzheimers Res Ther, 11, 30, 10.1186/s13195-019-0483-2 · DOI · Paper page
  33. van der Ende, 2021, Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions, J Neurol Neurosurg Psychiatry, 92, 502, 10.1136/jnnp-2020-325377 · DOI
  34. Bertrand, 2018, Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 years, JAMA Neurol, 75, 236, 10.1001/jamaneurol.2017.4266 · DOI · Paper page
  35. Jiskoot, 2019, Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia, Brain, 142, 193, 10.1093/brain/awy288 · DOI · Paper page
  36. Oxtoby, 2017, Data-driven sequence of changes to anatomical brain connectivity in sporadic Alzheimer's disease, Front Neurol, 8, 580, 10.3389/fneur.2017.00580 · DOI · Paper page

Cited by

See all 58

Metadata

Authors
van der Ende, E. L., Bron, E. E., Poos, J. M., Jiskoot, L. C., Panman, J. L., Papma, J. M., Meeter, L. H., Dopper, E. G. P., Wilke, C., Synofzik, M., Heller, C., Swift, I. J., Sogorb-Esteve, A., Bouzigues, A., Borroni, B., Sanchez-Valle, R., Moreno, F., Graff, C., Laforce, R., Galimberti, D., Masellis, M., Tartaglia, M. C., Finger, E., Vandenberghe, R., Rowe, J. B., de Mendonça, A., Tagliavini, F., Santana, I., Ducharme, S., Butler, C. R., Gerhard, A., Levin, J., Danek, A., Otto, M., Pijnenburg, Y. A. L., Sorbi, S., Zetterberg, H., Niessen, W. J., Rohrer, J. D., Klein, S., van Swieten, J. C., Venkatraghavan, V., Seelaar, H., GENFI consortium, Afonso, S., Almeida, M. R., Anderl-Straub, S., Andersson, C., Antonell, A., Archetti, S., Arighi, A., Balasa, M., Barandiaran, M., Bargalló, N., Bartha, R., Bender, B., Benussi, A., Benussi, L., Bessi, V., Binetti, G., Black, S., Bocchetta, M., Borrego-Ecija, S., Bras, J., Bruffaerts, R., Cañada, M., Cantoni, V., Caroppo, P., Cash, D., Castelo-Branco, M., Convery, R., Cope, T., Di Fede, G., Díez, A., Duro, D., Fenoglio, C., Ferrari, C., Ferreira, C. B., Fox, N., Freedman, M., Fumagalli, G., Gabilondo, A., Gasparotti, R., Gauthier, S., Gazzina, S., Giaccone, G., Gorostidi, A., Greaves, C., Guerreiro, R., Hoegen, T., Indakoetxea, B., Jelic, V., Karnath, H.-O., Keren, R., Langheinrich, T., Leitão, M. J., Lladó, A., Lombardi, G., Loosli, S., Maruta, C., Mead, S., Miltenberger, G., van Minkelen, R., Mitchell, S., Moore, K., Nacmias, B., Nicholas, J., Öijerstedt, L., Olives, J., Ourselin, S., Padovani, A., Peakman, G., Pievani, M., Pijnenburg, Y., Polito, C., Premi, E., Prioni, S., Prix, C., Rademakers, R., Redaelli, V., Rittman, T., Rogaeva, E., Rosa-Neto, P., Rossi, G., Rosser, M., Santiago, B., Scarpini, E., Schönecker, S., Semler, E., Shafei, R., Shoesmith, C., Tábuas-Pereira, M., Tainta, M., Taipa, R., Tang-Wai, D., Thomas, D. L., Thompson, P., Thonberg, H., Timberlake, C., Tiraboschi, P., Todd, E., Van Damme, P., Vandenbulcke, M., Veldsman, M., Verdelho, A., Villanua, J., Warren, J., Woollacott, I., Wlasich, E., & Zulaica, M.
Venue
Brain
Published
2021-10-11
Volume
145
Issue
5
Pages
1805-1817
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W3205797556
Cited by
58
References
28
FWCI
6.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.